dpp 4 and glp 1 together Dipeptidyl Peptidase Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus - Aloke - 2025 - Pharmacoepidemiology Drug Safety Dipeptidyl peptidase 4 inhibitors in

The key is gradual dose escalation, patience while steady-state levels build, and knowing that the full effect takes months to arrive

Fenfluramine, one of the earliest weight loss drugs, was found over time to be associated with valvular heart disease [48] and was withdrawn from the market by the FDA

doi:10.1046/j.1524-475X.1994.20406.x 9

JACC Basic Transl Sci 7(7):713715

Common side effects include: Nausea Vomiting Diarrhea Stomach pain Constipation Reduced appetite More serious risks may involve: Thyroid concerns Pancreatitis Gallbladder issues Vision changes Severe gastrointestinal (GI) complications Allergic reactions A healthcare provider should review your medical history before starting treatment